Asset Details
Do you wish to reserve the book?
Development of a novel multi-epitope mRNA vaccine candidate to combat SFTSV pandemic
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Development of a novel multi-epitope mRNA vaccine candidate to combat SFTSV pandemic
Do you wish to request the book?
Development of a novel multi-epitope mRNA vaccine candidate to combat SFTSV pandemic
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Development of a novel multi-epitope mRNA vaccine candidate to combat SFTSV pandemic
2025
Overview
Severe Fever with Thrombocytopenia Syndrome virus (SFTSV) is a novel identified pathogen, despite two decades of research on SFTSV, the potential widespread threats pose a significant challenge for researchers in developing new treatment and prevention methods. In this present, we have developed a multi-epitope mRNA vaccine for SFTSV and valid it with in silico methods. We screened 9 immunodominant epitopes for cytotoxic T cells (CTL), 7 for helper T cells (HTL), and 8 for Linear B-cell (LBL) based on promising candidate protein Gn, Gc, Np, and NSs. All predicted epitopes demonstrated strong antigenicity without any potential harm to humans. Additionally, the high conservancy is required to cover different strains. All epitopes as well as adjuvants were constructed into a final vaccine, which was further assesd by calculating of physicochemical properties. Then, we docked the vaccine protein with immune receptors and analyzed the complexes with dynamic simulations to evaluate its affinity to receptors. Finally, the vaccine sequence was constructed into a mRNA sequence. The constructed vaccine is a potential candidate for combating SFTSV by stimulating protective humoral and cellular immune responses.
Publisher
Public Library of Science,Public Library of Science (PLoS)
Subject
/ China
/ Control
/ Epitopes, B-Lymphocyte - genetics
/ Epitopes, B-Lymphocyte - immunology
/ Epitopes, T-Lymphocyte - genetics
/ Epitopes, T-Lymphocyte - immunology
/ Humans
/ Immunodominant Epitopes - genetics
/ Immunodominant Epitopes - immunology
/ Pandemics - prevention & control
/ T-Lymphocytes, Cytotoxic - immunology
/ Vaccines, Synthetic - genetics
